Ramizol®: A new treatment for Clostridium difficile associated disease

(Boulos and Cooper Pharmaceuticals Pty Ltd) A scientific paper released today in the Journal of Antibiotics presents the pre-clinical development of Ramizol®, a first generation drug belonging to a new class of styrylbenzene antibiotics with a novel mechanism of action.